PH48

ICD-11 MMS 2026-01

Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances

Index terms

  • Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances
  • drug related harm
  • Exposure to or harmful effects of undetermined intent of systemic antibiotics
Show allHide
  • Exposure to or harmful effects of undetermined intent of penicillins
  • Exposure to or harmful effects of undetermined intent of cephalosporins or other beta-lactam antibiotics
  • Exposure to or harmful effects of undetermined intent of chloramphenicol group
  • Exposure to or harmful effects of undetermined intent of macrolides
  • Exposure to or harmful effects of undetermined intent of tetracyclines
  • Exposure to or harmful effects of undetermined intent of aminoglycosides
  • Exposure to or harmful effects of undetermined intent of rifampicins
  • Exposure to or harmful effects of undetermined intent of antifungal antibiotics, systemically used
  • Exposure to or harmful effects of undetermined intent of other systemic anti-infectives or antiparasitics
  • Exposure to or harmful effects of undetermined intent of sulfonamides
  • Exposure to or harmful effects of undetermined intent of antimycobacterial drugs
  • Exposure to or harmful effects of undetermined intent of antimalarials or drugs acting on other blood protozoa
  • Exposure to or harmful effects of undetermined intent of other antiprotozoal drugs
  • Exposure to or harmful effects of undetermined intent of anthelminthics
  • Exposure to or harmful effects of undetermined intent of antiviral drugs
  • Exposure to or harmful effects of undetermined intent of hormones or their synthetic substitutes or antagonists, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of glucocorticoids or synthetic analogues
  • Exposure to or harmful effects of undetermined intent of thyroid hormones or substitutes
  • Exposure to or harmful effects of undetermined intent of antithyroid drugs
  • Exposure to or harmful effects of undetermined intent of insulin or oral hypoglycaemic drugs
  • harmful effect of antidiabetic drugs, undetermined intent
  • Exposure to or harmful effects of undetermined intent of oral contraceptives
  • Exposure to or harmful effects of undetermined intent of other estrogens or progestogens
  • Exposure to or harmful effects of undetermined intent of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of androgens or anabolic congeners
  • Exposure to or harmful effects of undetermined intent of unspecified hormones or synthetic substitutes
  • Exposure to or harmful effects of undetermined intent of anterior pituitary hormones
  • Harmful effect of adenohypophyseal hormones, undetermined intent
  • Exposure to or harmful effects of undetermined intent of other hormones or synthetic substitutes
  • Exposure to or harmful effects of undetermined intent of unspecified hormone antagonists
  • Exposure to or harmful effects of undetermined intent of other hormone antagonists
  • Exposure to or harmful effects of undetermined intent of drugs primarily affecting the autonomic nervous system
  • Exposure to or harmful effects of undetermined intent of anticholinesterase agents
  • Exposure to or harmful effects of undetermined intent of other parasympathomimetics
  • harmful effect of cholinergics, undetermined intent
  • Exposure to or harmful effects of undetermined intent of ganglionic blocking drugs
  • Exposure to or harmful effects of undetermined intent of other parasympatholytics or spasmolytics
  • harmful effect of anticholinergics or antimuscarinics, undetermined intent
  • Exposure to or harmful effects of undetermined intent of predominantly alpha-adrenoreceptor agonists
  • Exposure to or harmful effects of undetermined intent of predominantly beta-adrenoreceptor agonists
  • Exposure to or harmful effects of undetermined intent of alpha-adrenoreceptor antagonists
  • Exposure to or harmful effects of undetermined intent of beta-adrenoreceptor antagonists
  • Exposure to or harmful effects of undetermined intent of centrally-acting or adrenergic-neuron-blocking agents
  • Exposure to or harmful effects of undetermined intent of agents primarily affecting blood constituents
  • Exposure to or harmful effects of undetermined intent of diphenhydramine
  • Exposure to or harmful effects of undetermined intent of other H1-receptor antagonists
  • Exposure to or harmful effects of undetermined intent of antiallergic or antiemetic drugs
  • Exposure to or harmful effects of undetermined intent of antineoplastic antimetabolites
  • Exposure to or harmful effects of undetermined intent of antineoplastic natural products
  • Exposure to or harmful effects of undetermined intent of other antineoplastic drugs
  • Exposure to or harmful effects of undetermined intent of immunosuppressive agents
  • Exposure to or harmful effects of undetermined intent of vitamin B12, folic acid or other anti-megaloblastic-anaemia preparations
  • Exposure to or harmful effects of undetermined intent of enzymes
  • Exposure to or harmful effects of undetermined intent of iron or its compounds
  • Exposure to or harmful effects of undetermined intent of anticoagulants
  • Exposure to or harmful effects of undetermined intent of antithrombotic drugs
  • harmful effect of platelet aggregation inhibitors, undetermined intent
  • Exposure to or harmful effects of undetermined intent of thrombolytic drug
  • Exposure to or harmful effects of undetermined intent of anticoagulant antagonists, vitamin K or other coagulants
  • Exposure to or harmful effects of undetermined intent of other fibrinolysis-affecting drugs
  • Exposure to or harmful effects of undetermined intent of natural blood or blood products
  • Exposure to or harmful effects of undetermined intent of acidifying or alkalising agents
  • Exposure to or harmful effects of undetermined intent of other primarily systemic agents, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of plasma substitutes
  • Exposure to or harmful effects of undetermined intent of agents primarily affecting the cardiovascular system
  • Exposure to or harmful effects of undetermined intent of cardiac-stimulant glycosides or drugs of similar action
  • Exposure to or harmful effects of undetermined intent of calcium-channel blockers
  • Exposure to or harmful effects of undetermined intent of other antidysrhythmic drugs
  • Exposure to or harmful effects of undetermined intent of nitroglycerin, nitroglycerol, medicinal
  • Exposure to or harmful effects of undetermined intent of other coronary vasodilators
  • Exposure to or harmful effects of undetermined intent of angiotensin-converting-enzyme inhibitors
  • Exposure to or harmful effects of undetermined intent of other antihypertensive drugs
  • Exposure to or harmful effects of undetermined intent of antihyperlipidemic or antiarteriosclerotic drugs
  • Exposure to or harmful effects of undetermined intent of peripheral vasodilators
  • Exposure to or harmful effects of undetermined intent of antivaricose drugs, including sclerosing agents
  • Exposure to or harmful effects of undetermined intent of agents primarily affecting the gastrointestinal system
  • Exposure to or harmful effects of undetermined intent of histamine H2-receptor blockers
  • Exposure to or harmful effects of undetermined intent of other antacids or anti-gastric-secretion drugs
  • Exposure to or harmful effects of undetermined intent of stimulant laxatives
  • Exposure to or harmful effects of undetermined intent of saline or osmotic laxatives
  • Exposure to or harmful effects of undetermined intent of other laxatives
  • Exposure to or harmful effects of undetermined intent of digestants
  • Exposure to or harmful effects of undetermined intent of antidiarrhoeal drugs
  • Exposure to or harmful effects of undetermined intent of emetics
  • Exposure to or harmful effects of undetermined intent of agents primarily acting on smooth or skeletal muscles or the respiratory system
  • Exposure to or harmful effects of undetermined intent of oxytocic drugs
  • Exposure to or harmful effects of undetermined intent of skeletal muscle relaxants
  • harmful effect of neuromuscular blocking agents, undetermined intent
  • Exposure to or harmful effects of undetermined intent of other drugs acting on muscles
  • Exposure to or harmful effects of undetermined intent of unspecified drugs acting on muscles
  • Exposure to or harmful effects of undetermined intent of antitussives
  • Exposure to or harmful effects of undetermined intent of expectorants
  • Exposure to or harmful effects of undetermined intent of other anti-common-cold drugs
  • Exposure to or harmful effects of undetermined intent of salbutamol
  • Exposure to or harmful effects of undetermined intent of aminophylline, theophylline
  • Exposure to or harmful effects of undetermined intent of terbutaline
  • Exposure to or harmful effects of undetermined intent of antiasthmatics, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of topical agents primarily affecting skin or mucous membrane or ophthalmological, otorhinolaryngological or dental drugs
  • Exposure to or harmful effects of undetermined intent of topical corticosteroid preparations
  • Exposure to or harmful effects of iodine, antiseptic, undetermined intent
  • Exposure to or harmful effects of undetermined intent of silver nitrate
  • Exposure to or harmful effects of undetermined intent of other local antifungal, anti-infective or anti-inflammatory drugs
  • Exposure to or harmful effects of undetermined intent of antipruritics
  • Exposure to or harmful effects of undetermined intent of methyl salicylate
  • Exposure to or harmful effects of undetermined intent of other local astringents or local detergents
  • Exposure to or harmful effects of undetermined intent of emollients, demulcents or protectants
  • Exposure to or harmful effects of undetermined intent of podophyllin
  • Exposure to or harmful effects of undetermined intent of keratolytics, keratoplastics, or other hair treatment drugs or preparations
  • Exposure to or harmful effects of undetermined intent of ophthalmological drugs or preparations
  • Exposure to or harmful effects of undetermined intent of otorhinolaryngological drugs or preparations
  • Exposure to or harmful effects of undetermined intent of fluoride preparations
  • Exposure to or harmful effects of undetermined intent of other dental drugs, topically applied
  • Exposure to or harmful effects of undetermined intent of camphor
  • Exposure to or harmful effects of undetermined intent of agents primarily affecting water-balance or mineral or uric acid metabolism
  • Exposure to or harmful effects of undetermined intent of mineralocorticoids
  • Exposure to or harmful effects of undetermined intent of mineralocorticoids antagonists
  • Exposure to or harmful effects of undetermined intent of loop diuretics
  • harmful effect of high-ceiling diuretics, undetermined intent
  • Exposure to or harmful effects of undetermined intent of carbonic-anhydrase inhibitors
  • Exposure to or harmful effects of undetermined intent of benzothiadiazine derivatives
  • harmful effect of thiazides, undetermined intent
  • Exposure to or harmful effects of undetermined intent of other diuretics
  • Exposure to or harmful effects of undetermined intent of electrolytic, caloric or water-balance agents
  • Exposure to or harmful effects of undetermined intent of mineral salts, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of drugs affecting uric acid metabolism
  • Exposure to or harmful effects of undetermined intent of vitamin D or derivatives
  • Exposure to or harmful effects of undetermined intent of bisphosphonates
  • Exposure to or harmful effects of undetermined intent of appetite depressants
  • Exposure to or harmful effects of undetermined intent of antidotes or chelating agents, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of disulfiram
  • Exposure to or harmful effects of undetermined intent of alcohol deterrents, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of X-ray contrast media
  • Exposure to or harmful effects of undetermined intent of MRI contrast agents
  • Exposure to or harmful effects of undetermined intent of agents used for other scanning techniques
  • Exposure to or harmful effects of undetermined intent of other diagnostic agents
  • Exposure to or harmful effects of undetermined intent of lipotropic drugs
  • Exposure to or harmful effects of undetermined intent of pharmaceutical excipients
  • Exposure to or harmful effects of undetermined intent of herbal preparations or formulas
  • Exposure to or harmful effects of undetermined intent of dietary supplements, vitamins or minerals
  • Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of complementary or traditional medicines, unspecified
  • Exposure to or harmful effects of undetermined intent of vaccines immunoglobulins or other biological substances
  • Exposure to or harmful effects of undetermined intent of BCG vaccine
  • Exposure to or harmful effects of undetermined intent of typhoid or paratyphoid vaccine
  • Exposure to or harmful effects of undetermined intent of cholera vaccine
  • Exposure to or harmful effects of undetermined intent of plague vaccine
  • Exposure to or harmful effects of undetermined intent of tetanus vaccine
  • Exposure to or harmful effects of undetermined intent of diphtheria vaccine
  • Exposure to or harmful effects of undetermined intent of Haemophilus influenzae type b vaccines
  • exposure to or harmful effects of undetermined intent of H. influenzae type b vaccines
  • Exposure to or harmful effects of undetermined intent of pertussis vaccine, including combinations with a pertussis component
  • Exposure to or harmful effects of undetermined intent of mixed bacterial vaccines without a pertussis component
  • Exposure to or harmful effects of undetermined intent of other or unspecified bacterial vaccines
  • Exposure to or harmful effects of undetermined intent of smallpox vaccines
  • Exposure to or harmful effects of undetermined intent of measles vaccines
  • Exposure to or harmful effects of undetermined intent of mumps vaccines
  • Exposure to or harmful effects of undetermined intent of rubella vaccines
  • Exposure to or harmful effects of undetermined intent of polio vaccines
  • Exposure to or harmful effects of undetermined intent of yellow fever vaccines
  • Exposure to or harmful effects of undetermined intent of hepatitis A vaccines
  • Exposure to or harmful effects of undetermined intent of hepatitis B vaccines
  • Exposure to or harmful effects of undetermined intent of influenza vaccines
  • Exposure to or harmful effects of undetermined intent of rotavirus vaccines
  • Exposure to or harmful effects of undetermined intent of human papillomavirus vaccines
  • Exposure to or harmful effects of undetermined intent of other viral vaccines
  • Exposure to or harmful effects of undetermined intent of rickettsial vaccines
  • Exposure to or harmful effects of undetermined intent of protozoal vaccines
  • Exposure to or harmful effects of undetermined intent of hepatitis B immune globulin
  • Exposure to or harmful effects of undetermined intent of antivenin, antivenom
  • Exposure to or harmful effects of undetermined intent of immunoglobulin, not elsewhere classified
  • Exposure to or harmful effects of undetermined intent of other specified vaccines
  • Exposure to or harmful effects of undetermined intent of unspecified vaccines

Exclusions from above levels

  • http://id.who.int/icd/entity/1583926619 – Substances associated with injury or harm in therapeutic use

Sibling codes

  • PH40 – Exposure to or harmful effects of undetermined intent of opioids or related analgesics
  • PH41 – Exposure to or harmful effects of undetermined intent of sedative hypnotic drugs or other CNS depressants
  • PH42 – Exposure to or harmful effects of undetermined intent of psychostimulants
  • PH43 – Exposure to or harmful effects of undetermined intent of cannabinoids or hallucinogens
  • PH44 – Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs
  • PH45 – Exposure to or harmful effects of undetermined intent of antidepressants
  • PH46 – Exposure to or harmful effects of undetermined intent of antipsychotics
  • PH47 – Exposure to or harmful effects of undetermined intent of antiepileptics or antiparkinsonism drugs
  • PH49 – Exposure to or harmful effects of undetermined intent of multiple drugs, medicaments or biological substances

Foundation entity

Exposure to or harmful effects of undetermined intent of other or unspecified drugs, medicaments or biological substances – http://id.who.int/icd/entity/638046280

Allowed postcoordination axes

Part of: 23: External causes of morbidity or mortality